The University of Southampton
University of Southampton Institutional Repository

Cephalosporin-NO-donor prodrug PYRRO-C3D shows β-lactam-mediated activity against Streptococcus pneumoniae biofilms

Allan, Raymond, Kelso, Michael J., Rineh, Ardeshir, Yepuri, Nageshwar R., Feelisch, Martin, Soren, Odel, Brito-Mutunayagam, Sanjita, Salib, R.J., Stoodley, Paul, Clarke, Stuart C., Webb, Jeremy, Hall-Stoodley, Luanne and Faust, Saul (2017) Cephalosporin-NO-donor prodrug PYRRO-C3D shows β-lactam-mediated activity against Streptococcus pneumoniae biofilms Nitric Oxide

Record type: Article


Bacterial biofilms show high tolerance towards antibiotics and are a significant problem in clinical settings where they are a primary cause of chronic infections. Novel therapeutic strategies are needed to improve anti-biofilm efficacy and support reduction in antibiotic use. Treatment with exogenous nitric oxide (NO) has been shown to modulate bacterial signaling and metabolic processes that render biofilms more susceptible to antibiotics. We previously reported on cephalosporin-3’-diazeniumdiolates (C3Ds) as NO-donor prodrugs designed to selectively deliver NO to bacterial infection sites following reaction with β-lactamases. With structures based on cephalosporins, C3Ds could, in principal, also be triggered to release NO following β-lactam cleavage mediated by transpeptidases/penicillin-binding proteins (PBPs), the antibacterial target of cephalosporin antibiotics. Transpeptidase-reactive C3Ds could potentially show both NO-mediated anti-biofilm properties and intrinsic (β-lactam-mediated) antibacterial effects. This dual-activity concept was explored using Streptococcus pneumoniae, a species that lacks β-lactamases but relies on transpeptidases for cell-wall synthesis. Treatment with PYRRO-C3D (a representative C3D containing the diazeniumdiolate NO donor PYRRO-NO) was found to significantly reduce viability of planktonic and biofilm pneumococci, demonstrating that C3Ds can elicit direct, cephalosporin-like antibacterial activity in the absence of β-lactamases. While NO release from PYRRO-C3D in the presence of pneumococci was confirmed, the anti-pneumococcal action of the compound was shown to arise exclusively from the β-lactam component and not through NO-mediated effects. The compound showed similar potency to amoxicillin against S. pneumoniae biofilms and greater efficacy than azithromycin, highlighting the potential of C3Ds as new agents for treating pneumococcal infections.

PDF Allan et al. (2017) - Accepted Manuscript
Restricted to Repository staff only until 21 February 2018.
Download (1MB)

More information

Accepted/In Press date: 16 February 2017
e-pub ahead of print date: 21 February 2017
Keywords: Streptococcus pneumoniae;
Organisations: nCATS Group, Centre for Biological Sciences, Clinical & Experimental Sciences


Local EPrints ID: 406412
ISSN: 1089-8603
PURE UUID: 9bf9903e-f46f-4e2e-ac8c-7ca03cbbd98b
ORCID for Martin Feelisch: ORCID iD
ORCID for Saul Faust: ORCID iD

Catalogue record

Date deposited: 10 Mar 2017 10:46
Last modified: 16 Oct 2017 00:25

Export record


Author: Raymond Allan
Author: Michael J. Kelso
Author: Ardeshir Rineh
Author: Nageshwar R. Yepuri
Author: Martin Feelisch ORCID iD
Author: Odel Soren
Author: Sanjita Brito-Mutunayagam
Author: R.J. Salib
Author: Paul Stoodley
Author: Stuart C. Clarke
Author: Jeremy Webb
Author: Luanne Hall-Stoodley
Author: Saul Faust ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.